Q702

DRUG3 trials

Sponsors

Qurient Co., Ltd., M.D. Anderson Cancer Center

Conditions

Acute Myeloid LeukemiaAdvanced CancerCervical CancerEsophageal CancerGastric CancerHepatocellular CancerMetastatic CancerSolid Tumor

Phase 1

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

CompletedNCT04648254

Qurient Co., Ltd.Advanced Cancer, Metastatic Cancer, Solid Tumor

Start: 2020-11-18End: 2025-12-23Updated: 2025-12-30

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Active, not recruitingNCT05438420

Qurient Co., Ltd.Cervical Cancer, Esophageal Cancer, Gastric Cancer +1

Start: 2023-01-12End: 2028-03-30Target: 120Updated: 2026-02-24

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruitingNCT06445907

M.D. Anderson Cancer CenterAcute Myeloid Leukemia

Start: 2025-02-12End: 2028-07-01Updated: 2026-05-29

Related Papers

A phase 1b/2, open-label study of selective Axl, Mer and CSF1R inhibitor adrixetinib (Q702) in combination with intravenous pembrolizumab in patients with selected advanced solid tumors: Results of a phase 1 study (QRNT-008).

Journal of Clinical Oncology2025-05-28

Abstract CT072: First in human trial of Q702 in patients with advanced solid tumors

Cancer Research2025-04-25

Phase 1 Study of AXL/MER/CSF1R Inhibitor Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Blood2024-11-05

645 A phase 1B/2, open-label study of Q702 in combination with intravenous pembrolizumab in patients with selected advanced solid tumors

Regular and Young Investigator Award Abstracts2023-10-31

651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2023-10-31

Abstract 2255: Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors

Cancer Research2023-04-043 citations

A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.

Journal of Clinical Oncology2021-05-201 citations